Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling-Reference-Cited by-同舟云学术

Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

Published:2016-02-12 Issue:5 Volume:30 Page:1116-1125
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Argyropoulos K V,Vogel R,Ziegler C,Altan-Bonnet G,Velardi E,Calafiore M,Dogan A,Arcila M,Patel M,Knapp K,Mallek C,Hunter Z R,Treon S P,van den Brink M R M,Palomba M L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu20168.pdf

Reference47 articles.

1. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K . Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004; 117: 787–800.

2. Rajewsky K . Clonal selection and learning in the antibody system. Nature 1996; 381: 751–758.

3. Fu C, Turck CW, Kurosaki T, Chan AC . BLNK: a central linker protein in B cell activation. Immunity 1998; 9: 93–103.

4. Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci USA 2001; 98: 2582–2586.

5. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM . SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 1999; 274: 32662–32666.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial;Nature Communications;2024-08-11

2. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

3. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies;Frontiers in Immunology;2023-10-26

4. First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma;2023-09-21

5. MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges;Hemato;2023-09-13